-
1.发明申请
公开(公告)号：WO2023017095A1
公开(公告)日：2023-02-16
申请号：PCT/EP2022/072482
申请日：2022-08-10
Applicant: HM HERBAMEDICA GMBH , DENDROPHARM GMBH
Inventor： ZIERAU, Klaas , HOEHNE, David , MORÉ, Sam
Abstract: The present invention relates to formulations for administration of cannabis active agents, preferably, cannabis extracts. It provides a composition or kit comprising a plurality of cannabis active agents and a hyperbranched dendritic core-multishell-nanocarrier or core-shell nanocarrier, such as a hyperbranched dendritic polyglycerol nanocarrier, as well as corresponding pharmaceutical compositions and methods of preparing the same. Preferably, the cannabis active agents, e.g., THC and CBD, are stabilized by the nanocarrier, and their transdermal or transmucosal bioavailability is enhanced. The pharmaceutical compositions can be for use in treating a condition as a stand-alone pharmaceutical or an add-on pharmaceutical selected from the group comprising chronic pain, especially neuropathic pain, chronic inflammation, rheumatoid arthritis, diseases that are an expression of endocannabinoid deficiency, migraine, fibromyalgia, irritable bowel syndrome, Crohn's disease and ulcerative colitis, multiple sclerosis; nausea, vomiting, anxiety, Gilles-de-la-Tourette syndrome, Parkinson's disease, attention deficit disorder (ADD) post-traumatic stress disorder (PTSD) and sleep disorders, or as a potential antineoplastic therapeutic, as an add-on antiepileptic drug or for appetite stimulation.
-
公开(公告)号：WO2021043757A1
公开(公告)日：2021-03-11
申请号：PCT/EP2020/074326
申请日：2020-09-01
Applicant: BIOTEST AG
Inventor： KISTNER, Steffen , SCHÜTTRUMPF, Jörg , DAUFENBACH, Jens , HERBENER, Peter , UNGERER, Christopher , DE GROOT, Annie , MARTIN, William
IPC: A61K38/37
Abstract: The present invention relates to recombinant coagulation factors, in particular, recombinant Factor VIII (FVIII) proteins having an increased half-life. They comprise a heavy chain portion and a light chain portion of Factor VIII and at least two albumin binding domains, wherein at least one albumin binding domain is C-terminal to the heavy chain portion and at least one albumin binding domain is C-terminal to the light chain portion. If the protein is a single chain protein, the albumin binding domain(s) C-terminal to the heavy chain portion is/are N-terminal to the light chain portion. The protein of the invention may also be a de-immunized Factor VIII protein comprising specific point mutations at defined positions, which serve to reduce the immunogenicity, wherein the protein substantially retains its coagulant activity. The invention also relates to nucleic acids encoding the proteins of the invention, methods of producing them and pharmaceutical compositions comprising any of these, wherein the pharmaceutical composition preferably is for use in treatment of hemophilia A.
-
3.发明申请COMPOSITION COMPRISING SELF-ASSEMBLING PEPTIDES FOR USE IN TREATMENT OF GINGIVITIS, PERIODONTITIS AND/OR PERI-IMPLANTITIS 审中-公开包含自组装肽的组合物用于治疗牙龈炎，牙周炎和/或周围血管炎
公开(公告)号：WO2018033570A1
公开(公告)日：2018-02-22
申请号：PCT/EP2017/070758
申请日：2017-08-16
Applicant: CREDENTIS AG
Inventor： HUG, Michael , LYSEK, Dominikus Amadeus , KOCH, Franziska , JUNG, Ronald , MATHES, Stephanie , MEYER, Nina , HÄMMERLE, Christoph , BRÖSELER, Frank , PIELES, Uwe
Abstract: The present invention provides a composition comprising specific self-assembling peptides, which are capable of self-assembly at a pH below 7.5 and at least physiologic ionic strength, e.g., PI 1-4. PI 1-8, PI 1-14, PI 1-13, PI 1-12, PI 1-28, PI 1-29, PI 1-2, PI 1-5, PI 1-17, PI 1-19, PI 1-20, PI 1-12, PI 1-16, PI 1-18, PI 1-26 or PI 1-31 for use in treating an oral disease selected from the group consisting of gingivitis, periodontitis and/or peri-implantitis in a subject. Said composition may be used, after suitable cleaning procedures, for filling pockets formed adjacent to teeth in said diseases, which enhances tissue regeneration. The composition may be suitable for controlled release of an active agent, e.g., an antimicrobial or antibiotic agent. The invention also provides a kit suitable for said treatment further comprising self-assembling peptides suitable for forming a second layer on top of the first composition.
Abstract translation: 本发明提供了一种组合物，其包含特定的自组装肽，其能够在低于7.5的pH下和至少生理离子强度下自组装，例如PI 1-4。 PI 1-8，PI 1-14，PI 1-13，PI 1-12，PI 1-28，PI 1-29，PI 1-2，PI 1-5，PI 1-17，PI 1-19， PI 1-20，PI 1-12，PI 1-16，PI 1-18，PI 1-26或PI 1-31，用于治疗选自牙龈炎，牙周炎和/或周围组织的口腔疾病， 种植体炎。 所述组合物可在适当的清洁程序之后用于填充所述疾病中与牙齿相邻形成的凹穴，这增强了组织再生。 该组合物可适用于控制释放活性剂，例如抗微生物剂或抗生素剂。 本发明还提供适用于所述处理的试剂盒，其进一步包含适用于在第一组合物上形成第二层的自组装肽。
-
4.发明申请
公开(公告)号：WO2018033544A1
公开(公告)日：2018-02-22
申请号：PCT/EP2017/070684
申请日：2017-08-15
Inventor： BUNSE, Mario , EDES, Inan , UCKERT, Wolfgang , BUCHHOLZ, Christian J. , SCHNEIDER, Irene
IPC: C12N5/0783 , C07K14/12
CPC classification number: C12N5/163 , C07K14/12 , C07K14/705 , C07K2319/33 , C12N2510/04
Abstract: The invention relates to the field of immunology and immunotherapy, in particular, to adoptive T cell therapy of cancer utilizing T cell receptor (TCR)-engineered T cells. The invention provides novel methods and tools for identification and cloning of TCR, which are also applicable for identification of other receptors such as B cell receptors or antibodies. The invention provides immortalized cell lines able to induce subset specific (e.g. CD4 + or CD8 + specific) hybridization during co-culture, e.g., with primary lymphocytes of mice or men. The immortalized cells are engineered to express two mutated glycoproteins derived from the paramyxovirus family, namely hemagglutinin (H) and fusion (F) or a derivative thereof. H is a chimeric protein not able to bind to its natural ligands, fused to a targeting ligand capable of specifically binding to a specific cell surface antigen such as a lymphocytic subset-marking ligand (e.g. CD4 or CD8); fusion (F) mediates the fusion of cellular membranes of the immortalized cell line and cells, e.g., primary lymphocytes, H has bound to. The methods of the invention comprise preparing a hybridoma cell expressing a receptor, comprising steps of co-culturing a cell expressing a specific cell surface antigen and said receptor with the specific immortalized cells of the invention. The invention also relates to the hybridoma cells obtainable by said method.
Abstract translation: 本发明涉及免疫学和免疫疗法领域，具体涉及利用T细胞受体（TCR） - 工程化T细胞的癌症的过继性T细胞治疗。 本发明提供了鉴定和克隆TCR的新方法和工具，其也可用于鉴定其他受体如B细胞受体或抗体。 本发明提供了能够在共培养过程中，例如与小鼠或男性的原代淋巴细胞共同培养时诱导子集特异性（例如CD4 + / CD8 +特异性）杂交的永生化细胞系。 工程化永生化细胞以表达衍生自副粘病毒科的两种突变糖蛋白，即血凝素（H）和融合蛋白（F）或其衍生物。 H是不能与其天然配体结合的嵌合蛋白，与能够特异性结合特定细胞表面抗原如淋巴细胞亚群标记配体（例如CD4或CD8）的靶向配体融合; 融合体（F）介导永生化细胞系和细胞（例如H已结合的初级淋巴细胞）的细胞膜融合。 本发明的方法包括制备表达受体的杂交瘤细胞，其包括将表达特定细胞表面抗原的细胞和所述受体共同培养于本发明的特定永生化细胞的步骤。 本发明还涉及通过所述方法可获得的杂交瘤细胞。
-
5.发明申请
公开(公告)号：WO2016059018A1
公开(公告)日：2016-04-21
申请号：PCT/EP2015/073623
申请日：2015-10-13
Applicant: BERNHARD-NOCHT-INSTITUT FÜR TROPENMEDIZIN
Inventor： EMMERICH-PALOH, Petra , SCHMITZ, Herbert , DESCHERMEIER, Christina
IPC: G01N33/566 , G01N33/68
CPC classification number: G01N33/566 , G01N33/6854 , G01N2333/70535
Abstract: The present invention relates to the field of diagnostic or analytic methods. In particular, the inventors teach that an Fc receptor for IgM heavy chains (FcμR), in particular, Faim 3/Toso or CD351, or a functional fragment thereof, which preferably comprises the Ig-like domain of Faim 3/Toso, may be used for in vitro quantification of IgM or IgA antibodies, preferably, IgM, in the form of immune complexes, i.e., complexes formed by antigen and specific antibody. These immune complexes may be formed by mixing an antigen with a sample comprising antibodies. A method for detection and quantification of IgA or IgM antibodies in the form of immune complexes is also provided. This can be useful for diagnosis of infections, e.g., with a virus.
Abstract translation: 本发明涉及诊断或分析方法领域。 特别地，本发明人教导，优选包含Faim 3 / Toso的Ig样结构域的IgM重链（FcμR）的Fc受体，特别是Faim 3 / Toso或CD351或其功能片段可以是 用于体外定量免疫复合物形式的IgM或IgA抗体，优选IgM，即由抗原和特异性抗体形成的复合物。 可以通过将抗原与包含抗体的样品混合来形成这些免疫复合物。 还提供了以免疫复合物形式检测和定量IgA或IgM抗体的方法。 这可以用于诊断感染，例如用病毒。
-
Patent Agency Ranking
公开(公告)号：WO2014027012A1
公开(公告)日：2014-02-20
申请号：PCT/EP2013/066962
申请日：2013-08-14
Applicant: CREDENTIS AG
Inventor： HUG, Michael , LYSEK, Domenikus Amadeus
CPC classification number: A61K38/17 , A61K6/0017
Abstract: The invention relates to a method for preparing a composition for treating a tooth lesion, said composition comprising peptides that are capable of undergoing self-assembly at a certain pH. The compositions of the invention are highly suitable for being used in the medical field, in particular for remineralising a tooth lesion such as a subsurface caries lesion.
Abstract translation: 本发明涉及一种制备用于治疗牙齿损伤的组合物的方法，所述组合物包含能够在一定pH下进行自组装的肽。 本发明的组合物非常适合用于医疗领域，特别是用于再矿化牙齿病变如地下龋齿病变。
-
公开(公告)号：WO2023017153A1
公开(公告)日：2023-02-16
申请号：PCT/EP2022/072679
申请日：2022-08-12
Applicant: BIOTEST AG
Inventor： MANEG, Oliver , SOCHOR, Florian , MÖLLER, Wolfgang , OTT, Vera , SCHEICH, Christoph
Abstract: The present invention relates to the field of blood products, in particular, to fibrinogen and fibrinogen drug products. The invention provides a fibrinogen drug product in dry, e.g., lyophilized form having a residual moisture content of 2-5% (w/w). The inventors have found that said moisture content is advantageous for viral inactivation by dry heat, which leads to a particularly virus-safe and stable product. The invention further provides a fibrinogen drug product in dry, e.g., lyophilized form, that has an especially low number of subvisible particles (SVPs), and a batch of such drug products. It suitable for reconstitution of 1 g of fibrinogen in water for injection to obtain a fibrinogen solution comprising 6000 or less SVPs having a size of 10-100 µm and 600 or less SVPs having a size of 25-100 µm. Methods of preparing the drug products of the invention are also disclosed, as well as these drug products for use in treatment of fibrinogen-deficiency.
-
8.发明申请
公开(公告)号：WO2022123011A1
公开(公告)日：2022-06-16
申请号：PCT/EP2021/085200
申请日：2021-12-10
Inventor： PENNINGER, Josef , STADLMANN, Johannes
IPC: A61K38/17
Abstract: The present invention relates to an ACE2 polypeptide lacking an N-linked glycosylation or comprising a truncated N-linked glyco- sylation, e.g., at an amino acid corresponding to Asn90 and/or Asn322 of SEQ ID NO: 1; its use in a treatment of a coronavirus infection and methods of manufacturing the ACE2 polypeptide.
-
公开(公告)号：WO2022117797A1
公开(公告)日：2022-06-09
申请号：PCT/EP2021/084131
申请日：2021-12-03
Applicant: MEDIZINISCHE HOCHSCHULE HANNOVER
Inventor： SCHAMBACH, Axel , MORGAN, Michael , SCHOTT, Juliane , BÜNING, Hildegard , STAECKER, Hinrich , WARNECKE, Athanasia
Abstract: The present invention relates to the field of gene therapy for the treatment of sensorineural hearing loss. In particular, the invention discloses a composition comprising a 3rd generation lentiviral vector pseudotyped with a viral envelope glycoprotein capable of binding to a receptor expressed in a cell of the inner ear for use in the treatment or prevention of sensorineural hearing loss, wherein said composition has a viral titer of at least 107TU/mL and is administered to the inner ear of a subject suffering from or in danger to undergo sensorineural hearing loss. The viral envelope glycoprotein is capable of binding to a receptor selected from the group consisting of the LDL-receptor and LDL-R family members, the SLC1 A5-receptor, the Pit1 /2-receptor and the PIRYV-G-receptor. Preferably, the viral glycoprotein is MARAV-G, COCV-G, VSV-G, VSV-G ts or PIRYV-G, most preferably, MARAV-G. The lentiviral vector further comprises a cargo sequence comprising, e.g. a protein-coding gene, a miRNA, an shRNA, a IncRNA or an sgRNA, wherein expression of said cargo sequence in the cell of the inner ear is capable of reducing, eliminating or preventing at least a symptom of sensorineural hearing loss in the subject. The invention further discloses a method for treating sensorineural hearing loss in a subject in need thereof.
-
公开(公告)号：WO2022084528A1
公开(公告)日：2022-04-28
申请号：PCT/EP2021/079393
申请日：2021-10-22
Inventor： POMBO, Ana , SPARKS, Thomas
IPC: C12Q1/6813 , C12Q1/6841
Abstract: The present invention relates to the field of nucleic acid sequencing at the single cell level, e.g., single-cell RNA sequencing (scRNA-seq). In particular, the invention provides a method of detecting nucleic acid in a fixated or non-fixated nucleic acid-containing compartment such as a eukaryotic cell or nucleus thereof, by hybridizing a plurality of single-stranded (ss)DNA oligonucleotide probes to complementary nucleic acid molecules within said compartment; removing ssDNA oligonucleotide probes from the compartment that have not specifically hybridized to nucleic acid; and identifying the ssDNA oligonucleotide probes specifically hybridized to nucleic acid molecules within said compartment by sequencing or amplification, thereby determining the corresponding nucleic acids present in said compartment. The method does not require a step of sequential ssDNA probe hybridization to the same target nucleic acid as a means for increased specificity or sensitivity, and preferably further does not require steps of RNA isolation and cDNA generation. The method of the invention has the potential to detect substantially every known and/or unknown nucleic acid species, in particular RNA, e.g., protein-encoding mRNAs as well as non-coding RNAs. The method further enables spatial mapping of detected nucleic acids, wherein the compartment is sectioned or dissociated into a single cell suspension prior to probe hybridization to obtain a collection of fractions and thus nucleic acid molecules are separated from each other depending on their localization or which cell type they belonged to. Spatial mapping of detected nucleic acids may be combined with the detection of at least one DNA locus, at least one protein, or with the analysis of chromatin condensation. The method of the invention is designated oligo-seq.
-
-
-
-
-
-
-
-
-
Search Results
55
records
(took 0.017 seconds)
